| Cat. No. |
Product Name |
Information |
| PC-45121 |
WY-14643
PPARα agonist
|
A potent, selective PPARα agonist with EC50 of 0.63 uM. |
| PC-42713 |
GW 501516
PPARδ agonist
|
GW 501516 (GW516) is a potent and subtype-selective PPARδ agonist with Ki of 1.1 nM in human PPARδ binding assay. |
| PC-45209 |
Rosiglitazone
PPARγ agonist
|
Rosiglitazone (BRL49653) is a potent and selective PPARγ agonist that binds to the PPARγ ligand-binding domain with a Kd of 40 nM. |
| PC-42693 |
BMS-687453
PPARα agonist
|
BMS-687453 (BMS687453) is a potent and selective PPARα agonist with EC50 of 10 nM for human PPARα and 410-fold selectivity over human PPARγ in PPAR-GAL4 transactivation assays. |
| PC-44041 |
Aleglitazar
PPARα/γ agonist
|
Aleglitazar (R1439, RO 0728804) is a potent and balanced dual PPARα/γ agonist (EC50= 50/21 nM). |
| PC-45752 |
Saroglitazar
PPARα agonist
|
Saroglitazar is a PPAR agonist with predominant PPARα and moderate PPARγ activity with EC50 of 0.65 pM and 3 nM respectively. |
| PC-45067 |
Elafibranor
PPARα/δ agonist
|
Elafibranor (GFT-505) is a potent dual PPAR α/δ agonist with EC50 of 45 and 175 nM, respectively. |
| PC-45390 |
Pemafibrate
PPARα agonist
|
Pemafibrate (K-877) is a highly potent, specific PPARα agonist with EC50 of 1 nM. |
| PC-22387 |
GW0742
PPARδ agonist
|
GW0742 is a potent, selective small molecule agonist of PPARδ with EC50 of 1.0 nM, 1000-fold selectivity over the other human PPAR subtypes. |
| PC-22386 |
LDT409
PPAR agonist
|
LDT409 is a small molecule, orally active partial agonist of pan PPARα/γ/δ with EC50 of 0.5 uM, 0.9 uM and 33 uM for huamn PPARα and PPARγ, respectively. |
| PC-22207 |
E09241
Osteoprotegerin upregulator, PPARδ activator
|
E09241 is a small molecule osteoprotegerin (OPG) upregulator with EC50 of 1.23 uM, effectively promotes osteogenesis and inhibits osteoclastogenesis through activating the PPARδ signaling pathway. |
| PC-22205 |
E0924G
Osteoprotegerin upregulator, PPARδ activator
|
E0924G is a small molecule osteoprotegerin (OPG, EC50=0.29 uM) and runt-related transcription factor 2 (RUNX2) upregulator, effectively promotes osteogenesis and inhibits osteoclastogenesis through activating the PPARδ signaling pathway. |
